Acute myocardial infarction is one of the leading causes of death in the developed world. The prevalence of the disease approaches three million people worldwide, with more than one million deaths in the United States annually. Acute myocardial infarction can be divided into two categories, non-ST-segment elevation MI (NSTEMI) and ST-segment elevation MI (STEMI). Unstable angina is similar to NSTEMI. However, cardiac markers are not elevated.
An MI results in irreversible damage to the heart muscle due to a lack of oxygen. An MI may lead to impairment in diastolic and systolic function and make the patient prone to arrhythmias. In addition, an MI can lead to a number of serious complications. The key is to reperfuse the heart and restore blood flow. The earlier the treatment (less than 6 hours from symptom onset), the better the prognosis.
An MI is diagnosed when two of the following criteria are met:
The etiology of acute myocardial infarction is decreased coronary blood flow. The available oxygen supply cannot meet oxygen demand, resulting in cardiac ischemia. Decreased coronary blood flow is multifactorial. Atherosclerotic plaques classically rupture and lead to thrombosis, contributing to acutely decreased blood flow in the coronary. Other etiologies of decreased oxygenation/myocardial ischemia include coronary artery embolism, which accounts for 2.9% of patients, cocaine-induced ischemia, coronary dissection, and coronary vasospasm.
Nonmodifiable risk factors
Modifiable risk factors
Other causes of MI
Among patients suffering from acute myocardial infarction, 70% of fatal events are due to occlusion from atherosclerotic plaques. As atherosclerosis is the predominant cause of acute myocardial infarction, risk-factors for atherosclerotic disease are often mitigated in the prevention of disease. Modifiable risk factors account for 90% (men) and 94% (female) of myocardial infarctions. Modifiable risk factors include cigarette smoking, exercise, hypertension, obesity, cholesterol, LDL, and triglyceride levels. In contrast, age, sex, and family history are non-modifiable risk factors for atherosclerosis.
Atherosclerotic rupture leads to an inflammatory cascade of monocytes and macrophages, thrombus formation, and platelet aggregation. This leads to decreased oxygen delivery through the coronary artery resulting in decreased oxygenation of the myocardium. The inability to produce ATP in the mitochondria leads to the ischemic cascade, and therefore apoptosis (cell death) of the endocardium, or myocardial infarction.
With some exceptions due to genetic variation, coronary arteries have unique and diagnostic territorial distributions. For example, the left anterior descending coronary artery supplies blood flow to the interventricular septum, anterolateral wall, and ventricular apex. The left circumflex artery supplies blood to the inferolateral wall. The right coronary artery supplies the right ventricle. The inferior wall is supplied either by the left circumflex or right coronary artery. 
The histology of myocardial infarction changes over the time-course of the disease. At time 0, there are no microscopic histologic changes. Under light microscopy, within 0.5 to 4 hours, waviness of fibers at the periphery of the tissue is seen. Glycogen is depleted. At 4 to 12 hours, the myocardium undergoes coagulation necrosis and edema. At 12 to 24 hours, the gross specimen becomes dark and mottled. There are contraction band necrosis and neutrophil predominance on histopathology. At 1 to 3 days, there is a loss of nuclei, and at 3 to 7 days, macrophages appear to remove apoptosis cells. At 7 to10 days, granulation tissue appears. At 10 days and onward, there is collagen one deposition. After 2 months, the myocardium is scarred.
Cardiac biomarkers are useful in the diagnosis of acute myocardial infarction, specifically non-ST-elevation MI. Troponin is the most specific lab test and has two isoforms, I and T. Troponins peak at 12 hours and persist for seven days. Creatinine kinase MB is also specific to the myocardium. It peaks at ten hours; however, it normalizes within two to three days. LDH peaks over 72 hours and normalizes over ten to 14 hours. In clinical practice, LDH is not used to diagnose acute MI. Finally, MB has very low specificity for myocardium and is not used clinically; it quickly rises and normalizes. High-sensitivity troponin has recently been approved for use in the United States after having been heavily studied and utilized in Europe. Although it is more sensitive than conventional troponin, it is also less specific. Thus, potential challenges include numerous false-positive interpretations.
The history of and physical exam is often inconsistent when evaluating for acute myocardial infarction. The history should focus on the onset, quality, and associated symptoms. Recent studies have found that diaphoresis and bilateral arm radiating pain most often are associated with myocardial infarction in men. Associated symptoms include:
Physical exam, most importantly, should note vital signs and patient’s appearance, including diaphoresis, as well as lung findings, and cardiac auscultation.
Early and rapid ECG testing should be employed in all patients presenting with chest pain. Women often have atypical symptoms such as abdominal pain or dizziness and may present without chest pain at all. Elderly patients more often have shortness of breath as their presenting symptom for myocardial infarction. All of these presentations should prompt ECG testing, as well.
The ECG is highly specific for MI (95% to 97%), yet not sensitive (approximately 30%). Right-sided, posterior lead placement, and repeat ECG testing can increase ECG sensitivity. For example, peaked T-waves on ECG, known as “hyperacute T waves,” often indicate early ischemia and will progress to ST elevation. When present, findings of ST-elevations greater than 2 mm in two contiguous leads on ECG (inferior: leads II, III, aVF; septal equal V1, V2; anterior: V3, V4; lateral: I, aVL, V5, V6) are indicative of an ST-elevation myocardial infarction. Often, there are ST depressions that are visualized in opposite anatomical regions of the myocardium.
ECG diagnosis of STEMI can be difficult, particularly in patients with a left bundle branch block and pacemakers. Sgarbosa described criteria that can assist the physician or practitioner in diagnosing STEMI in these patients. Isolated ST-elevations in aVR are indicative of left main coronary artery occlusion in the appropriate clinical setting. Wellens noted deeply biphasic T waves in V2, V3, and found they are often predictive of an impending proximal left anterior descending artery occlusion, which may lead to devastating anterior wall myocardial infarction.
Patients that present with myocardial infarction may not have diagnostic ST-elevation ECG abnormalities. Patients with typical chest pain should be investigated for NSTEMI with subtle abnormalities on ECG, including ST-depressions and T wave changes. Serial ECGs can be helpful here as well to look for dynamic changes. ECG without acute changes or any abnormalities is common in NSTEMI.
There are diagnostic guidelines that can assist the practitioner in determining whether further testing is useful in identifying patients with NSTEMI. Given the poor sensitivity of ECG for STEMI, troponins are almost universally used for patients with a suspicious clinical history. The HEART score has been validated and popularized. It utilizes clinician’s suspicion, patient risk factors, ECG diagnostics, and troponin level to determine the “risk level” of the patient.
B-type natriuretic peptide (BNP) should not be ordered as a marker for MI, but it is better used to stratify risk, especially in patients with MI who develop heart failure.
Cardiac angiography is used to perform percutaneous coronary intervention (PCI) or determine obstructions in the coronary vessels.
An echocardiogram is used to assess wall motion, degree of valve abnormality, ischemic mitral regurgitation (MR), and presence of cardiac tamponade.
All patients with STEMI and NSTEMI require immediately chewed aspirin 160 mg to 325 mg. Furthermore, the patient should have intravenous access and oxygen supplementation if oxygen saturation is less than 91%. Opioids may be used for pain control in addition to sublingual nitroglycerin if the blood pressure is adequate.
Treatment for STEMI includes immediate reperfusion. Preference is for emergent percutaneous coronary intervention (PCI). Before PCI, patients should receive dual antiplatelet agents, including intravenous heparin infusion as well as an adenosine diphosphate inhibitor receptor (P2Y2 inhibitor), most commonly ticagrelor. Furthermore, glycoprotein IIb/IIIa inhibitor or direct thrombin inhibitor may be given at the time of percutaneous intervention.
If percutaneous intervention is unavailable within 90 minutes of the diagnosis of STEMI, reperfusion should be attempted with an intravenous thrombolytic agent.
NSTEMI in a stable asymptomatic patient may not benefit from emergent percutaneous coronary intervention and should be managed medically with antiplatelet agents. Percutaneous coronary intervention can be done within 48 hours of admission and may lead to improved in-hospital mortality and decreased length of stay. In NSTEMI patients with refractory ischemia or ischemia with hemodynamic or electrical instability, PCI should be performed emergently
Before discharge for acute MI, patients may routinely be given aspirin, high-dose statin, beta-blocker, and/or ACE-inhibitor.
If PCI is contemplated, it should be done within 12 hours. If fibrinolytic therapy is considered, it should be done within 120 minutes. Parenteral anticoagulation, in addition to antiplatelet therapy, is recommended for all patients.
Acute MI still carries a high mortality rate, with most of the deaths occurring prior to arrival to the hospital. At least 5%-10% of survivors die within the first 12 months after the MI, and close to 50% need hospitalization within the same year. The overall prognosis depends on the extent of muscle damage. Good outcomes are seen in patients who undergo early perfusion- thrombolytic therapy within 30 minutes of arrival or PCI within 90 minutes). In addition, outcomes are good if the ejection fraction is preserved and the patient is started in aspirin, beta-blockers, and ACE inhibitors.
Factors that negatively affect prognosis include:
Acute myocardial infarction is managed by an interprofessional team that is solely dedicated to heart disease. Besides the cardiologist, the team usually consists of a cardiac surgeon, an interventional cardiologist, intensivist, cardiac rehabilitation specialist, critical care or cardiology nurses, and physical therapists. Because many patients die before even reaching the hospital, the key is to educate the patient on symptoms and early arrival to the emergency department.
The pharmacist, nurse practitioner, and primary care providers should educate patients on how to take nitroglycerin, and if there is no relief after three doses, then 911 should be called.
At triage, the nurse should immediately communicate with the interprofessional team as time to reperfusion is limited. The cardiologist may consider thrombolysis or PCI, depending on the duration of symptoms and contraindications. All patients need ICU monitoring. Nurses should be vigilant about the potentially life-threatening complications and communicate with the team if there are abnormal clinical signs or laboratory parameters. No patient should e prematurely discharged because complications of an MI can occur up to a week after an MI. After stabilization, patients need thorough education by the nurse on the reduction of risk factors for coronary artery disease. Besides a nurse practitioner, the social worker should be involved to facilitate home care, cardiac rehab, and the need for any support services while at home. The pharmacist should address and provide education concerning appropriate medication dosing and discuss potential side effects.
After discharge, the patient needs to enter a cardiac rehabilitation program, eat a healthy diet, discontinue smoking, abstain from alcohol, reduce body weight, and lower cholesterol and blood glucose levels. The patient should be educated on the importance of compliance with medications to lower blood pressure and blood cholesterol. [Level 2] Pharmacists review prescribed medications, check for interactions, and provide patient education about the importance of compliance. [Level 5]
Acute myocardial infarction continues to have high mortality out of the hospital. Data indicate that at least one-third of patients die before coming to the hospital, and another 40%-50% are dead upon arrival. Another 5%-10% of patients will die within the first 12 months after their myocardial infarction. Readmission is common in about 50% of patients within the first 12 months after the initial MI. The overall prognosis depends on the ejection fraction, age, and other associated comorbidity. Those who do not undergo any revascularization will have a poorer outcome compared to patients who undergo revascularization. The best prognosis is in patients with early and successful reperfusion and preserved left the ventricular function. [Level 2]
|||Nascimento BR,Brant LCC,Marino BCA,Passaglia LG,Ribeiro ALP, Implementing myocardial infarction systems of care in low/middle-income countries. Heart (British Cardiac Society). 2018 Sep 29 [PubMed PMID: 30269080]|
|||Barberi C,van den Hondel KE, The use of cardiac troponin T (cTnT) in the postmortem diagnosis of acute myocardial infarction and sudden cardiac death: A systematic review. Forensic science international. 2018 Sep 17 [PubMed PMID: 30269044]|
|||Alaour B,Liew F,Kaier TE, Cardiac Troponin - Diagnostic Problems and Impact on Cardiovascular Disease. Annals of medicine. 2018 Sep 28 [PubMed PMID: 30265127]|
|||Massberg S,Polzin A, [Update ESC-Guideline 2017: Dual Antiplatelet Therapy]. Deutsche medizinische Wochenschrift (1946). 2018 Aug [PubMed PMID: 30060279]|
|||Scheen AJ, [From atherosclerosis to atherothrombosis : from a silent chronic pathology to an acute critical event]. Revue medicale de Liege. 2018 May [PubMed PMID: 29926559]|
|||Berg DD,Wiviott SD,Braunwald E,Guo J,Im K,Kashani A,Gibson CM,Cannon CP,Morrow DA,Bhatt DL,Mega JL,O'Donoghue ML,Antman EM,Newby LK,Sabatine MS,Giugliano RP, Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European heart journal. 2018 Sep 20 [PubMed PMID: 30239711]|
|||Deng D,Liu L,Xu G,Gan J,Shen Y,Shi Y,Zhu R,Lin Y, Epidemiology and Serum Metabolic Characteristics of Acute Myocardial Infarction Patients in Chest Pain Centers. Iranian journal of public health. 2018 Jul [PubMed PMID: 30182001]|
|||Haig C,Carrick D,Carberry J,Mangion K,Maznyczka A,Wetherall K,McEntegart M,Petrie MC,Eteiba H,Lindsay M,Hood S,Watkins S,Davie A,Mahrous A,Mordi I,Ahmed N,Teng Yue May V,Ford I,Radjenovic A,Welsh P,Sattar N,Oldroyd KG,Berry C, Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights. JACC. Cardiovascular imaging. 2018 Jul 13 [PubMed PMID: 30031700]|
|||Alquézar-Arbé A,Sanchís J,Guillén E,Bardají A,Miró Ò,Ordóñez-Llanos J, Cardiac troponin measurement and interpretation in the diagnosis of acute myocardial infarction in the emergency department: a consensus statement. Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias. 2018 Oct [PubMed PMID: 30260119]|
|||Perera M,Aggarwal L,Scott IA,Logan B, Received care compared to ADP-guided care of patients admitted to hospital with chest pain of possible cardiac origin. International journal of general medicine. 2018 [PubMed PMID: 30214268]|
|||Riley RF,Miller CD,Russell GB,Soliman EZ,Hiestand BC,Herrington DM,Mahler SA, Usefulness of Serial 12-Lead Electrocardiograms in Predicting 30-Day Outcomes in Patients With Undifferentiated Chest Pain (the ASAP CATH Study). The American journal of cardiology. 2018 Aug 1 [PubMed PMID: 30196932]|
|||Larson E,German DM,Shatzel J,DeLoughery TG, Anticoagulation in the Cardiac Patient: A Concise Review. European journal of haematology. 2018 Sep 10 [PubMed PMID: 30203452]|
|||Bath PM,Woodhouse LJ,Appleton JP,Beridze M,Christensen H,Dineen RA,Flaherty K,Duley L,England TJ,Havard D,Heptinstall S,James M,Kasonde C,Krishnan K,Markus HS,Montgomery AA,Pocock S,Randall M,Ranta A,Robinson TG,Scutt P,Venables GS,Sprigg N, Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. Health technology assessment (Winchester, England). 2018 Aug [PubMed PMID: 30179153]|
|||Adamski P,Adamska U,Ostrowska M,Navarese EP,Kubica J, Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert opinion on pharmacotherapy. 2018 Sep [PubMed PMID: 30132731]|
|||Aeyels D,Seys D,Sinnaeve PR,Claeys MJ,Gevaert S,Schoors D,Sermeus W,Panella M,Bruyneel L,Vanhaecht K, Managing in-hospital quality improvement: An importance-performance analysis to set priorities for ST-elevation myocardial infarction care. European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2018 Aug [PubMed PMID: 29448818]|
|||Schwaab B, [Cardiac Rehabilitation]. Die Rehabilitation. 2018 Apr [PubMed PMID: 29216666]|
|||El Hajj MS,Jaam MJ,Awaisu A, Effect of pharmacist care on medication adherence and cardiovascular outcomes among patients post-acute coronary syndrome: A systematic review. Research in social [PubMed PMID: 28641999]|
|||Stone GW,Ellis SG,Gori T,Metzger DC,Stein B,Erickson M,Torzewski J,Williams J Jr,Lawson W,Broderick TM,Kabour A,Piegari G,Cavendish J,Bertolet B,Choi JW,Marx SO,Généreux P,Kereiakes DJ, Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet (London, England). 2018 Sep 24 [PubMed PMID: 30266412]|
|||Lopes RD,de Barros E Silva PGM,de Andrade Jesuíno I,Santucci EV,Barbosa LM,Damiani LP,Nakagawa Santos RH,Laranjeira LN,Dall Orto FTC,Beraldo de Andrade P,de Castro Bienert IR,Alexander JH,Granger CB,Berwanger O, Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial. JAMA cardiology. 2018 Sep 24 [PubMed PMID: 30264159]|
|||Choi AR,Jeong MH,Hong YJ,Sohn SJ,Kook HY,Sim DS,Ahn YK,Lee KH,Cho JY,Kim YJ,Cho MC,Kim CJ, Clinical characteristics and outcomes in acute myocardial infarction patients with versus without any cardiovascular risk factors. The Korean journal of internal medicine. 2018 Sep 1 [PubMed PMID: 30257551]|